IBDEI0HD ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7556,1,3,0)
 ;;=3^PLEURAL BIOPSY
 ;;^UTILITY(U,$J,358.3,7557,0)
 ;;=32554^^62^492^2^^^^1
 ;;^UTILITY(U,$J,358.3,7557,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7557,1,2,0)
 ;;=2^32554
 ;;^UTILITY(U,$J,358.3,7557,1,3,0)
 ;;=3^ASPIRATE PLEURA W/O IMAGING
 ;;^UTILITY(U,$J,358.3,7558,0)
 ;;=32555^^62^492^1^^^^1
 ;;^UTILITY(U,$J,358.3,7558,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7558,1,2,0)
 ;;=2^32555
 ;;^UTILITY(U,$J,358.3,7558,1,3,0)
 ;;=3^ASPIRATE PLEURA W/ IMAGING
 ;;^UTILITY(U,$J,358.3,7559,0)
 ;;=99291^^62^493^1^^^^1
 ;;^UTILITY(U,$J,358.3,7559,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7559,1,2,0)
 ;;=2^99291
 ;;^UTILITY(U,$J,358.3,7559,1,3,0)
 ;;=3^CRITICAL CARE E&M,30-74 MIN
 ;;^UTILITY(U,$J,358.3,7560,0)
 ;;=99292^^62^493^2^^^^1
 ;;^UTILITY(U,$J,358.3,7560,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7560,1,2,0)
 ;;=2^99292
 ;;^UTILITY(U,$J,358.3,7560,1,3,0)
 ;;=3^CRITICAL CARE E&M,EA ADDL 30 MIN
 ;;^UTILITY(U,$J,358.3,7561,0)
 ;;=G0425^^62^494^1^^^^1
 ;;^UTILITY(U,$J,358.3,7561,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7561,1,2,0)
 ;;=2^G0425
 ;;^UTILITY(U,$J,358.3,7561,1,3,0)
 ;;=3^INPT/TELECONSULT,INIT,30 MIN
 ;;^UTILITY(U,$J,358.3,7562,0)
 ;;=G0426^^62^494^2^^^^1
 ;;^UTILITY(U,$J,358.3,7562,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7562,1,2,0)
 ;;=2^G0426
 ;;^UTILITY(U,$J,358.3,7562,1,3,0)
 ;;=3^INPT/TELECONSULT,INIT,50 MIN
 ;;^UTILITY(U,$J,358.3,7563,0)
 ;;=G0427^^62^494^3^^^^1
 ;;^UTILITY(U,$J,358.3,7563,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7563,1,2,0)
 ;;=2^G0427
 ;;^UTILITY(U,$J,358.3,7563,1,3,0)
 ;;=3^INPT/TELECONSULT,INIT,70 MIN
 ;;^UTILITY(U,$J,358.3,7564,0)
 ;;=G0406^^62^494^4^^^^1
 ;;^UTILITY(U,$J,358.3,7564,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7564,1,2,0)
 ;;=2^G0406
 ;;^UTILITY(U,$J,358.3,7564,1,3,0)
 ;;=3^INPT/TELE FOLLOW-UP,15 MIN
 ;;^UTILITY(U,$J,358.3,7565,0)
 ;;=G0407^^62^494^5^^^^1
 ;;^UTILITY(U,$J,358.3,7565,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7565,1,2,0)
 ;;=2^G0407
 ;;^UTILITY(U,$J,358.3,7565,1,3,0)
 ;;=3^INPT/TELE FOLLOW-UP,25 MIN
 ;;^UTILITY(U,$J,358.3,7566,0)
 ;;=G0408^^62^494^6^^^^1
 ;;^UTILITY(U,$J,358.3,7566,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7566,1,2,0)
 ;;=2^G0408
 ;;^UTILITY(U,$J,358.3,7566,1,3,0)
 ;;=3^INPT/TELE FOLLOW-UP,35 MIN
 ;;^UTILITY(U,$J,358.3,7567,0)
 ;;=G0459^^62^494^7^^^^1
 ;;^UTILITY(U,$J,358.3,7567,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,7567,1,2,0)
 ;;=2^G0459
 ;;^UTILITY(U,$J,358.3,7567,1,3,0)
 ;;=3^INPT/TELE PHARM MGMT
 ;;^UTILITY(U,$J,358.3,7568,0)
 ;;=I63.50^^63^495^1
 ;;^UTILITY(U,$J,358.3,7568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7568,1,3,0)
 ;;=3^Cerebral Infarction d/t Occls/Stenosis of Unspec Cerebral Artery
 ;;^UTILITY(U,$J,358.3,7568,1,4,0)
 ;;=4^I63.50
 ;;^UTILITY(U,$J,358.3,7568,2)
 ;;=^5007343
 ;;^UTILITY(U,$J,358.3,7569,0)
 ;;=I63.511^^63^495^2
 ;;^UTILITY(U,$J,358.3,7569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7569,1,3,0)
 ;;=3^Cerebral Infarction d/t Occls/Stenosis of Right Mid Cerebral Artery
 ;;^UTILITY(U,$J,358.3,7569,1,4,0)
 ;;=4^I63.511
 ;;^UTILITY(U,$J,358.3,7569,2)
 ;;=^5007344
 ;;^UTILITY(U,$J,358.3,7570,0)
 ;;=I63.512^^63^495^3
 ;;^UTILITY(U,$J,358.3,7570,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7570,1,3,0)
 ;;=3^Cerebral Infarction d/t Occls/Stenosis of Left Mid Cerebral Artery
 ;;^UTILITY(U,$J,358.3,7570,1,4,0)
 ;;=4^I63.512
